Literature DB >> 10874665

Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.

T Günther1, R Schneider-Stock, C Häckel, H U Kasper, M Pross, A Hackelsberger, H Lippert, A Roessner.   

Abstract

Mdm2, localized on chromosome 12, is considered a negative regulator of p53 function and seems to play a role in the pathogenesis of a variety of tumors. The mdm2 amplification in advanced-stage gastric carcinoma has not yet been investigated. Mdm2 amplification was determined in 43 gastric carcinomas, and the genetic results were correlated with mdm2 protein expression, p53 alterations, and clinicopathologic data. The tumors were classified according to Lauren: 20 intestinal-type tumors, 19 tumors of diffuse growth inclusive of a primary small cell carcinoma, and 4 carcinomas with mixed differentiation. Staging was based on the pTNM classification system. Mdm2 and p53 were demonstrated by immunohistology on formalin-fixed and paraffin-embedded tumor tissue. The mdm2 oncogene was amplified by nonradioactive hybridization of tumor DNA with an mdm2 cDNA probe. The Southern blots were evaluated densitometrically. For p53 mutation screening, we analyzed the highly conservative regions of the p53 gene (exons 4 to 8) with the use of the polymerase chain reaction-single-strand conformation polymorphism technique. Polymerase chain reaction products with band shifting were directly sequenced. Mdm2 amplification was demonstrated in 18 tumors (41.8%). The mdm2 gene was amplified more frequently in carcinomas with a diffuse growth pattern. Gastric carcinomas of the intestinal type, however, showed a higher frequency of p53 alterations. There was no statistical significance of the molecular genetic and immunohistologic results of the mdm2/p53 status to staging as well as to age and sex of the patients. The mdm2/p53 pathway is a part of the carcinogenesis of gastric carcinoma. Only approximately 20% of gastric carcinomas failed to show mdm2 and/or p53 alterations. The upregulation of the mdm2 oncogene and the accompanying inactivation of the tumor suppressor gene 53 seem to play a role above all in carcinomas of the diffuse type.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10874665     DOI: 10.1038/modpathol.3880107

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  27 in total

Review 1.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

2.  [Spindle-cell osteosclerotic bone lesion with MDM2 amplification].

Authors:  C Mogler; M Boxberg; C Knebel; W Weichert; K Wörtler; K Specht
Journal:  Pathologe       Date:  2018-03       Impact factor: 1.011

3.  Disseminated Superficial Porokeratosisin a Patient with Gastric Cancer.

Authors:  Shin Woo Kim; Seong Uk Min; Chong Hyun Won; Soyun Cho
Journal:  Ann Dermatol       Date:  2008-12-31       Impact factor: 1.444

4.  Genetic mutations of p53 and k-ras in gastric carcinoma patients from Hunan, China.

Authors:  Han-Chun Chen; Hui-Juan Chen; Md Asaduzzaman Khan; Zhou-Zhou Rao; Xin-Xing Wan; Bo Tan; Dian-Zheng Zhang
Journal:  Tumour Biol       Date:  2010-11-16

5.  Expression and significance of p53 and mdm2 in atypical intestinal metaplasia and gastric carcinoma.

Authors:  Lin Wang; Xiao-Ying Zhang; Ling Xu; Wen-Jun Liu; Juan Zhang; Jian-Ping Zhang
Journal:  Oncol Lett       Date:  2011-04-14       Impact factor: 2.967

6.  Serum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer.

Authors:  Pei Li; Jian-Xiang Shi; Li-Ping Dai; Yu-Rong Chai; Hong-Fei Zhang; Mutombo Kankonde; Peggy Kankonde; Bao-Fa Yu; Jian-Ying Zhang
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

Review 7.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

Authors:  Sanjeev Shangary; Shaomeng Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

8.  Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors.

Authors:  Qin Li; Yun Zhang; Adel K El-Naggar; Shunbin Xiong; Peirong Yang; James G Jackson; Gilda Chau; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2014-03-05       Impact factor: 5.852

9.  Association of Murine Double Minute 2 polymorphisms with gastric cancer: A systematic review with meta-analysis.

Authors:  Mafalda Timóteo; Ana Tavares; Sara Cruz; Carla Campos; Rui Medeiros; Hugo Sousa
Journal:  Biomed Rep       Date:  2021-06-17

10.  The Expression of Murine Double Minute 2 (MDM2) on Helicobacter pylori-Infected Intestinal Metaplasia and Gastric Cancer.

Authors:  Noriko Nakajima; Yoko Ito; Kiyoshi Yokoyama; Akitake Uno; Noriko Kinukawa; Norimichi Nemoto; Mitsuhiko Moriyama
Journal:  J Clin Biochem Nutr       Date:  2009-02-28       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.